Petco Health & Wellness Co., Inc. (WOOF)
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-09-04
$2.70+7.14%
Close 2026-09-04 · 1-day change
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-09-04
QuarterlyIQ Insights · WOOF
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.70 WOOF trades at 11× p/e, below its 11× p/e peer median. Our $4.16 fair value sits well above the price. We hold it with medium confidence: quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $3.25–$4.14. Note: our $4.16 fair value sits above the entire analyst range ($3.25–$4.14). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $4.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $21.11 | — | — | Hist. CAGR | high |
| graham number | 12M | $4.69 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $2.73 | 8.9 | 0.95 | TTM | high |
| Peer P/FCF |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
$3.25 – $4.14 (median $4.00) · 3 analysts · as of 2026-09-03
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
| 12M |
| $11.62 |
| 14.2 |
| 0.82 |
| TTM |
| high |
| Peer P/E | 12M | $2.70 | 11.3 | 0.24 | TTM | high |
| Peer P/S | 12M | $8.41 | 0.4 | 20.95 | TTM | high |
| PEG | 12M | $3.86 | 16.1 | 0.24 | TTM | high |
| residual income | 12M | $3.71 | — | — | TTM | high |
| Own P/E history | 12M | $4.63 | 19.3 | 0.24 | TTM | high |
| triangulated | 12M | $2.80 | 11.3 | 0.25 | Triangulated | high |
| Peer P/FCF | 3Y | $17.67 | 14.2 | 1.24 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $2.94 | 11.3 | 0.26 | Analyst | medium |
| Peer P/S | 3Y | $8.75 | 0.4 | 21.81 | Analyst | medium |
| PEG | 3Y | $4.19 | 16.1 | 0.26 | Analyst | medium |
| Own P/E history | 3Y | $5.03 | 19.3 | 0.26 | Analyst | medium |
| Peer P/FCF | 5Y | $23.37 | 14.2 | 1.65 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $3.01 | 11.3 | 0.27 | Analyst | medium |
| Peer P/S | 5Y | $8.98 | 0.4 | 22.38 | Analyst | medium |
| PEG | 5Y | $4.30 | 16.1 | 0.27 | Analyst | medium |
| Own P/E history | 5Y | $5.16 | 19.3 | 0.27 | Analyst | medium |